Speratum is a pre-clinical stage biotechnology company developing RNA-based therapeutics for the treatment of cancer and other diseases. Speratum's foundational technologies were developed at Baylor College of Medicine that combine to generate a safe and effective platform for nucleic acid therapies

Speratum has developed a polymeric drug delivery system that can be preferentially targeted to specific cells, as well as a proprietary RNA-based molecular scaffold for therapeutic application of multiple miRNA and siRNA based therapeutics. Speratum's lead candidate is an miRNA drug for the treatment of pancreatic, ovarian, and other cancers. Speratum operates the only AAALAC-certified animal care and use program in the Central American region.